Humanizing Early Drug Discovery and Preclinical Safety Testing with Physiological iPS Cell Models
Recorded February 10, 2016
The recording of the webinar is available in full length here
Webinar Description:
Learn how human cardiac cells, derived from induced pluripotent stem cells (iPSC), are playing a rapidly increasing role in in vitro drug discovery & development assays in the pharmaceutical industry. From high-throughput screening (HTS) to toxicology testing, human cardiac cells can be applied in pure 2D cultures for desired controls as well as 3D co-culture systems for physiological relevance. Whether you are screening for new drug targets, or investigating drug effects on electrophysiology, contractility, or cardiac-specific toxicity, this seminar will provide insights for your own research.
Learning Objectives:
Uses of iPSC-derived cell types in screening/safety applications
Humanize drug discovery/development, “Mimic Clinic”
‘Real-world’ examples / case studies
Axiogenesis background / overview, products/services
Speakers:
Thomas Licher, PhD
Group Leader Lead Identification Technologies (LIT) Biology
Sanofi
Andrew Bruening-Wright, PhD
Principal Scientist Discovery, Charles River
Charles River
Ralf Kettenhofen, PhD
Head of Lab
Axiogenesis
Moderator:
Brian Murphy
Director Marketing & Sales
Axiogenesis